PYC Therapeutics Stock

PYC Therapeutics EBIT

The EBIT of PYC Therapeutics (PYC.AX) as of Aug 13, 2026 is -49.75 M AUD. In the previous year, EBIT was -37.57 M AUD — a change of 32.42% (lower).

EBIT

-49.75 MAUD

YoY

32.42%

Last updated:

In 2026, PYC Therapeutics's EBIT was -49.75 M AUD, a 32.42% increase from the -37.57 M AUD EBIT recorded in the previous year.

The PYC Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined AUD)
Date
EBIT (undefined AUD)
Jan 1, 2022
0.00 base
Jan 1, 2023
0.00 base
Jan 1, 2024
0.00 base
Jan 1, 2025
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
YEAREBIT (undefined AUD)
2029 est -
2028 est -
2027 est -
2026 est -
2025 -
2024 -
2023 -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

PYC Therapeutics Revenue

PYC Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
16.07 M AUD
-14.26 M AUD
-13.86 M AUD
Jan 1, 2023
15.89 M AUD
-23.28 M AUD
-22.79 M AUD
Jan 1, 2024
22.86 M AUD
-37.57 M AUD
-37.73 M AUD
Jan 1, 2025
26.17 M AUD
-49.75 M AUD
-50.30 M AUD
Jan 1, 2026 (e)
5.05 M AUD
-76.43 M AUD
-68.79 M AUD
Jan 1, 2027 (e)
17.68 M AUD
-127.54 M AUD
-61.41 M AUD
Jan 1, 2028 (e)
120.42 M AUD
-150.85 M AUD
135.77 M AUD
Jan 1, 2029 (e)
53.13 M AUD
-99.76 M AUD
-20.70 M AUD

PYC Therapeutics Margins

PYC Therapeutics stock margins

The PYC Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PYC Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PYC Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
-612,400.00 %
-88.76 %
-86.28 %
Jan 1, 2023
-612,400.00 %
-146.49 %
-143.43 %
Jan 1, 2024
-612,400.00 %
-164.37 %
-165.06 %
Jan 1, 2025
-612,400.00 %
-190.08 %
-192.21 %
Jan 1, 2026 (e)
-612,400.00 %
-1,513.50 %
-1,362.21 %
Jan 1, 2027 (e)
-612,400.00 %
-721.61 %
-347.41 %
Jan 1, 2028 (e)
-612,400.00 %
-125.27 %
112.75 %
Jan 1, 2029 (e)
-612,400.00 %
-187.77 %
-38.97 %

PYC Therapeutics Stock analysis

What does PYC Therapeutics do? PYC Therapeutics Ltd is a biopharmaceutical company based in Sydney, Australia. The company was founded in 2017 by experienced pharmaceutical and biotech managers and currently employs over 40 employees. The history of PYC Therapeutics began with the development of a novel therapy platform called "PCytTM", which is based on the use of artificial proteins. These proteins can enhance the uptake of drugs into cells, thereby increasing the effectiveness of various medications. In 2018, PYC Therapeutics achieved a significant milestone by being included in the prestigious Accelerating Commercialisation program of the Australian government. PYC Therapeutics' business model focuses on the research and development of innovative cancer therapies and rare genetic diseases. The company strives to focus on diseases for which there is currently no effective treatment. This is intended to be achieved through partnerships, licensing, and potentially through the acquisition of companies and technologies. PYC Therapeutics shapes its processes through collaboration with experts in the fields of medicine, pharmacy, biotechnology, and chemistry. The divisions of PYC Therapeutics can be divided into the following areas of activity: drug development, platform technology, partnerships, and research and development. Under drug development, PYC Therapeutics understands the actual production of new cancer therapeutics and medications for the treatment of rare genetic diseases. The company relies on its internal research and also utilizes in-licensed technologies and acquisitions to develop novel drugs. Platform technology is a key success factor for PYC Therapeutics. The company has developed a highly effective method with PCytTM to optimize drug transport. This can significantly enhance the efficacy of medications. This technology has the potential to revolutionize the treatment of many diseases. Partnerships are an important part of PYC Therapeutics' business model. The company focuses on long-term collaborations with large pharmaceutical and biotech companies. This cooperation is intended to accelerate the development, approval, and commercialization of new medications. Research and development form the core of PYC Therapeutics' business model. The company invests significantly in the exploration of new therapeutics for cancer and rare genetic diseases. Since its inception, the company has continuously expanded its development platform and has become a key player in the industry. One of PYC Therapeutics' most important pipeline products is "PYC-06". PYC-06 is a medication developed for the treatment of acute myeloid leukemia (AML). The therapy aims to enhance the potential of chemotherapeutics by using PCytTM. The initial results of clinical studies show very promising results. Overall, PYC Therapeutics is an important player in the field of innovative cancer care and the treatment of rare genetic diseases. The company has a strong pipeline of novel therapeutics based on its PCytTM technology. PYC Therapeutics strives to improve the treatment of cancer and rare diseases and achieve a better quality of life for patients. The business model of PYC Therapeutics focuses on partnerships, innovative developments, and scientific research that contribute to advancing the industry. PYC Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing PYC Therapeutics's EBIT

PYC Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PYC Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PYC Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PYC Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PYC Therapeutics stock

EBIT of PYC Therapeutics is -49.75 M AUD in 2026.

EBIT of PYC Therapeutics changed from -37.57 M AUD to -49.75 M AUD, representing a 32.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT PYC Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's PYC Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — PYC Therapeutics

All Key Metrics — PYC Therapeutics